Liver Transplant Recipients
Conditions
Keywords
Liver transplantation, Everolimus, Sirolimus, Treatment outcome, Safety
Brief summary
This study aims to determine the safety and efficacy of conversion of sirolimus to everolimus in the maintenance treatment of LT recipients. Patients will be monitored every 12 weeks after the switch of treatment for 48 weeks. The laboratory tests including hematological, renal, hepatic, and metabolic parameters will be performed at each visit. Twenty-four-hour urine creatinine clearance and proteinuria will be determined from a 24-hour urine collection at baseline and week 48.
Detailed description
Everolimus (EVL) and sirolimus (SRL), an antagonist of mammalian target of rapamycin, has been introduced into solid organ transplantation to either replace or reduce the dose of potentially nephrotoxic calcineurin inhibitors. Although not approved for liver transplantation (LT), SRL has still been used in several LT centers. After EVL was approved by FDA and the Ministry of Health in Turkey for use in LT recipients, SRL was converted to EVL in our institution. This study aims to determine the safety and efficacy of conversion of SRL to EVL in the maintenance treatment of LT recipients. Patients who switch from SRL to EVL will be monitored every 12 weeks after the switch of treatment for 48 weeks. Efficacy measure will be included any observation in terms of biopsy-proven acute/chronic rejection and graft or patient loss due to rejection. Safety evaluations will be included discontinuation of EVL and analyses of adverse events and grading laboratory abnormalities. Laboratory evaluations will be included hematological (CBC), renal (serum creatinine, estimated glomerular filtration rate \[eGFR; Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI)\], and electrolytes), hepatic (serum transaminases, alkaline phosphatase, γ-glutamyl transferase, bilirubin, and albumin), and metabolic parameters (fasting glucose, cholesterol, and triglyceride) at each visit. Twenty-four-hour urine creatinine clearance and proteinuria will be determined from a 24-hour urine collection at baseline and week 48. For patients who were on additional immunosuppressive treatments, those medications will also be continued.
Interventions
None listed
Sponsors
Ege University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients older than 18 years * Liver transplant recipients who switch from sirolimus to everolimus
Exclusion criteria
* Patients who refuse the everolimus switching
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with advers events, biopsy-proven acute/chronic rejection, graft loss, or death from switching time to 48 weeks post-conversion. | 48 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory follow-up (hepatic) | At baseline and Weeks 12, 24, 36, and 48 | It will include serum transaminases, alkaline phosphatase, γ-glutamyl transferase, bilirubin, and albumin |
| Laboratory follow-up (renal) | At baseline and Weeks 12, 24, 36, and 48 | It will include serum creatinine, eGFR (MDRD and CKD-EPI), and electrolytes (sodium, potassium, calcium, magnesium, and phosphate) |
| Laboratory follow-up (metabolic) | At baseline and Weeks 12, 24, 36, and 48 | It will include fasting glucose, cholesterol, and triglyceride. |
| Laboratory follow-up (hematological) | At baseline and Weeks 12, 24, 36, and 48 | It will include complete blood count (hemoglobin, hematocrit, leukocyte, and platelet) |
| Laboratory follow-up (24-hour urine proteinuria) | At baseline and Week 48 | — |
| Median dose of everolimus | 48 weeks | The median dose of everolimus to reach the therapeutic range (3 - 8 ng/mL) |
| Laboratory follow-up (24-hour urine creatinine clearance) | At baseline and Week 48 | — |
Countries
Turkey (Türkiye)
Outcome results
None listed